pentafluorophenyl chloroformate | 36919-02-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: pentafluorophenyl chloroformate
• 英文别名: Chlorameisensaeure-(2,3,4,5,6-pentafluorphenyl)ether；Pentafluorphenoxycarbonylchlorid；(2,3,4,5,6-pentafluorophenyl) carbonochloridate
• CAS: 36919-02-5
• 化学式: C₇ClF₅O₂
• 分子量: 246.521
• InChiKey: PQBYMIGEEFVPNG-UHFFFAOYSA-N

物化性质

• 沸点：
  53 °C(Press: 13 Torr)
• 密度：
  1.724±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  pentafluorophenyl chloroformate 在 盐酸 、 甲酸 、 牛血清白蛋白 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 pentafluorophenyl N-<(methoxysuccinyl)-L-alanyl-L-alanyl-L-prolylmethyl>-N-isopropylcarbamate
  参考文献：
  名称：

  Peptidyl carbamates incorporating amino acid isosteres as novel elastase inhibitors

  摘要：

  The design and synthesis of 13 novel peptidyl carbamates are described. When tested for inhibitory activity toward porcine pancreatic elastase, trypsin, and chymotrypsin, six compounds were found to specifically inhibit elastase without affecting the other two serine proteases. All the active inhibitors had an amino acid isostere at the P1 position. Kinetic studies indicated that the inhibition was competitive with Ki values ranging from 4.23 X 10(-5) to 2.4 X 10(-6) M. The degree of inhibition was found to be dependent on the specificity of the peptide chain for the extended subsites on the enzyme as well as on the nature of P1'. Preliminary work on one inhibitor indicates that the inhibition is reversible and proceeds via the rapid formation of a strong enzyme-inhibitor complex, followed by slow acylation of the serine residue on the active site of the enzyme. Peptidyl carbamates represent a novel class of elastase inhibitors.

  DOI：

  10.1021/jm00158a025
• 作为产物：
  描述：

  五氟苯酚 、 氯甲酸三氯甲酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以79%的产率得到pentafluorophenyl chloroformate
  参考文献：
  名称：

  A Convenient Method for the Synthesis of ActivatedN-Methylcarbamates

  摘要：

  报道了一种高效制备活性N-甲基氨基甲酸酯的方法。由相应氯甲酸酯5a-e制备了N-（甲基氨基甲酰氧基）琥珀酰亚胺（3a）、芳基N-甲基氨基甲酸酯3b-d和2,2,2-三氟-1-（三氟甲基）乙基N-甲基氨基甲酸酯（3e），产率为70-80%。这些氯甲酸酯是通过三氯甲基氯甲酸酯（1）或双（三氯甲基）碳酸酯（2）与羟基化合物4a-e的缩合反应，以高产率制备的结晶固体。

  DOI：

  10.1055/s-1993-25809

文献信息

• [EN] CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS<br/>[FR] SUPPORTS SOLIDES POUR LA LIBÉRATION CONTRÔLÉE DE MÉDICAMENTS
  申请人：PROLYNX LLC

  公开号：WO2011140392A1

  公开（公告）日：2011-11-10

  The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.

  这项发明涉及在医疗应用中有用的固体支持物，可提供药物的控制释放，如肽、核酸和小分子。这些药物通过一个通过受控β消除释放药物或前药的连接与固体支持物共价偶联。
• CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Renz Martin

  公开号：US20100331320A1

  公开（公告）日：2010-12-30

  This invention relates to novel compounds of the Formula Ik, Im 1 , Im 2 , Im 5 , In 1 , In 2 , In 5 , Io 1 , Io 2 , Io 5 , Ip 1 , Ip 3 , pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  这项发明涉及到Ik、Im1、Im2、Im5、In1、In2、In5、Io1、Io2、Io5、Ip1、Ip3的新化合物，以及其药学上可接受的盐和药物组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
• [EN] CYCLIC INHIBITORS OF 11ß-HYDROXYSTERIOD DEHYDROGENASE 1<br/>[FR] INHIBITEURS CYCLIQUES DE LA 11?-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE 1
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2009017664A1

  公开（公告）日：2009-02-05

  This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及式(I)、(Ia)、(Ib)、(Ic)、(Id)、(Ie)、(If)、(Ig)、(Ih)；(Ii)；(Ij)，(Ik)，(II)的新颖化合物，其药用可接受的盐以及药物组合物，这些化合物对于治疗与调节或抑制哺乳动物中的11β-HSD1相关的疾病是有用的。本发明进一步涉及新颖化合物的药物组合物及其在减少或控制细胞中皮质醇的产生或抑制细胞中将可的松转化为皮质醇的方法。
• [EN] CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE<br/>[FR] INHIBITEURS CYCLIQUES DE LA 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE 1 BASÉE SUR LA STRUCTURE 1,3-OXAZINAN-2-ONE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2011011123A1

  公开（公告）日：2011-01-27

  This invention relates to substitued 1, 3-oxazin-2-one compounds of the Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  这项发明涉及Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B)的取代1,3-噁唑-2-酮化合物，以及其药学上可接受的盐和药物组合物，用于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法的用途。
• CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
  申请人：Fresenius Kabi Deutschland GmbH

  公开号：US20150297738A1

  公开（公告）日：2015-10-22

  The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

  本发明涉及一种羟烷基淀粉共轭物及其制备方法，所述羟烷基淀粉共轭物包括羟烷基淀粉衍生物和细胞毒性药剂，所述细胞毒性药剂包括至少一个次级羟基，其中羟烷基淀粉通过所述次级羟基与细胞毒性药剂连接。根据本发明的共轭物具有以下公式HAS'(-L-M)n的结构，其中M是细胞毒性药剂的残基，L是连接基团，HAS'是羟烷基淀粉衍生物的残基，n大于或等于1，且羟烷基淀粉衍生物的平均分子量（MW）高于肾脏阈值。